The present invention relates to the use of bacterial compositions having an
arginine deiminase activity (inhibition of
nitric oxide synthase by conversion of L-
arginine to L-
citrulline) of 1-1,000 μmol L-
citrulline / h / g composition and a sphingomyelinase (
ceramide generation) activity of 0.01-1.000 nmoles ceramides / h / g composition in the treatment and / or prophylaxis of
airway diseases caused by viruses such as influenza viruses, coronaviruses, as SARS-CoV, MERS-CoV and SARS-CoV-2, avian viruses, respiratory syncytial
virus (VRS), rhinoviruses, pneumoviruses, or
respiratory failure induced or aggravated by viral infections,
angina pectoris, pulmonary heart,
respiratory distress,
pulmonary edema, neonatal
asphyxia,
myocardial infarction,
heart failure,
respiratory failure Pickwick syndrome,
pulmonary hypertension, pneumonia or even
cystic fibrosis (CF) aggravated by viral infections.